Voya Investment Management LLC Has $68.61 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Voya Investment Management LLC has decreased its stake in Edwards Lifesciences Corporation by 29.1%, owning approximately 946,537 shares valued at $68.6 million following the sale of 389,401 shares in the first quarter.
• Various institutional investors have recently adjusted their positions, including Wealth Enhancement Advisory Services LLC, which increased its holdings by 13.5% during the same period.
• Edwards Lifesciences reported a quarterly earnings per share (EPS) of $0.67, surpassing analyst expectations of $0.62, with revenue increasing by 11.9% year-over-year to $1.53 billion.

Voya Investment Management LLC trimmed its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 29.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 946,537 shares of the medical research company's stock after selling 389,401 shares during the period. Voya Investment Management LLC owned approximately 0.16% of Edwards Lifesciences worth $68,605,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Arlington Trust Co LLC lifted its position in Edwards Lifesciences by 1.2% in the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock worth $804,000 after purchasing an additional 135 shares during the period. Valeo Financial Advisors LLC lifted its position in Edwards Lifesciences by 2.8% in the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock worth $372,000 after purchasing an additional 142 shares during the period. Versant Capital Management Inc lifted its position in Edwards Lifesciences by 9.3% in the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock worth $123,000 after purchasing an additional 145 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after acquiring an additional 145 shares during the last quarter. Finally, Kera Capital Partners Inc. lifted its position in shares of Edwards Lifesciences by 5.0% during the 1st quarter. Kera Capital Partners Inc. now owns 3,090 shares of the medical research company's stock valued at $224,000 after acquiring an additional 148 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Down 1.4%

NYSE:EW traded down $1.02 during trading hours on Thursday, hitting $74.18. 3,657,195 shares of the stock traded hands, compared to its average volume of 4,444,600. The firm has a 50 day moving average price of $78.84 and a 200 day moving average price of $75.47. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The firm has a market cap of $43.55 billion, a price-to-earnings ratio of 10.66, a PEG ratio of 3.62 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the business earned $0.70 EPS. The company's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on EW. Daiwa America upgraded Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft increased their price objective on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Wall Street Zen downgraded Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 13th. Piper Sandler increased their price objective on Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a research report on Friday, July 25th. Finally, Evercore ISI increased their price objective on Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $87.17.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.